Serum adipocyte fatty acid binding protein in liver transplant recipients and the metabolic syndrome
Journal Title: Annals of Hepatology - Year 2012, Vol 11, Issue 3
Abstract
Background. Liver transplantation is often associated with metabolic derangements. Adipocyte fatty-acid-binding protein 4 (AFABP4) integrates inflammatory and metabolic responses. It has also been associated with metabolic syndrome in animal models and clinical studies in the general population. Aim. To determine the role of AFABP4 in post-transplant metabolic syndrome. Material and methods. Consecutive patients followed for at least 6 months after liver transplantation were tested for insulin resistance by homeostasis model assessment (HOMA). Serum levels of AFABP4 were tested by an enzyme-linked immunosorbent assay. Results. The study group included 76 patients (64.5% male, mean age 56.3 ± 12.4 years). Hypertension waspresent in 56.5%, hyperlipidemia in 69.7%, diabetes mellitus in 23.6%. Half of the patients met at least 3 criteria for metabolic syndrome. Serum AFABP4 levels (p < 0.0001), HOMA index ≥ 2.5 vs. < 2.5 (p < 0.0002) and BMI ≥ 30 vs. < 30 (p < 0.0006) were significantly higher in patients with metabolic syndrome. Within the metabolic syndrome subgroup, AFABP4 levels significantly correlated with age, aspartate aminotransaminase level, waist circumference, and HOMA index. High AFABP4 significantly increased the odds of acquiring metabolic syndrome (OR 1.04, 95% CI 1.007-1.074, p = 0.017). On multiple logistic regression analysis, independent predictors of high AFABP4 were cryptogenic liver disease, steroid administration, high HOMA index, and a high degree of fatty infiltration. Conclusion. Prevalence of metabolic syndrome is significantly higher in liver transplant recipients than in the general population. AFABP4 may serve as a circulating biomarker in the clinical prediction/diagnosis of metabolic syndrome in patients post-liver transplantation.
Authors and Affiliations
Hemda Schmilovitz-Weiss, Ido Laish, Zohar Levi, Yehudith Monsselise, Yael Harif, Marius Braun, Mona Boaz, Ziv Ben-Ari
Keywords
Related Articles
- EP ID EP78146
- DOI -
- Views 117
- Downloads 0
Gut microbiota and nonalcoholic fatty liver disease
Recent evidence has linked obesity and the metabolic syndrome with gut dysbiota. The precise mechanisms underlying that association are not entirely understood; however, microbiota can enhance the extraction of energy f...
The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women
Introduction and aim. Given that early identification of non-alcoholic fatty liver disease (NAFLD) is an important issue for primary prevention of hepatic disease, the objectives of this study were to evaluate the effic...
An Acknowledgeme
Serum homocysteine levels in patients with nonalcoholic fatty liver disease
Background and rational for the study. Nonalcoholic fatty liver disease (NAFLD) is regarded as the hepatic component of insulin resistance (IR) syndrome, but data on serum homocysteine (HCY) are limited. The aim of the s...
Platelet count/spleen diameter ratio as a predictor of esophageal varices in cirrhotic patients - Reply